Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910466 · ClinicalTrials.gov registry record · Phase 4
A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
A Phase 4 study of Hypoparathyroidism and Chronic Hypoparathyroidism, sponsored by Shire.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02910466: Completed Phase 4 study of Hypoparathyroidism and Chronic Hypoparathyroidism, sponsored by Shire.
NCT02910466 is a Phase 4 study of Hypoparathyroidism and Chronic Hypoparathyroidism that has completed, run by Shire. The registered enrollment target is 39 participants, below the 196-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910466, a Phase 4 study of Hypoparathyroidism and Chronic Hypoparathyroidism, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic hypoparathyroidism is a life-long and irreversible disease for which the chronic administration of rhPTH(1-84) is a potential treatment option. The group of participants in the AAAE0544 core study has been taking rhPTH(1-84) for the treatment of hypoparathyroidism for up to 11 years. This study is designed to extend this experience and gain knowledge about how safe and effective rhPTH(1-84) is in participants with hypoparathyroidism over a long-term duration.
Primary Outcome
Baseline (402) was defined as the last available pre-dose value in SHP634-402.
Conditions Studied
Interventions
- DRUG rhPTH(1-84)
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-10-27 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 4 |
What the finished NCT02910466 record still lists
NCT02910466 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 196-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which rhPTH(1-84) is the first listed.
NCT02910466 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02910466 about?
NCT02910466 is a clinical study titled "A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism". Chronic hypoparathyroidism is a life-long and irreversible disease for which the chronic administration of rhPTH(1-84) is a potential treatment option. The group of participants in the AAAE0544 core study has been taking rhPTH(1-84) for the treatment of hypoparathyroidism for up to 11 years. This st...
What is the current status of trial NCT02910466?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2016-10-27. Estimated completion is 2019-12-20.
What conditions does trial NCT02910466 study?
This clinical trial studies the following conditions: Hypoparathyroidism, Chronic Hypoparathyroidism.
What interventions are being tested in trial NCT02910466?
The interventions under investigation include: rhPTH(1-84) (DRUG).
Who is sponsoring clinical trial NCT02910466?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02910466 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02910466's enrollment target sits among peer trials
39 9th of 10 higher than 2 of 10 other Hypoparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
COMPLETED · Phase 4
-
A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)
COMPLETED · Phase 4
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI